SCHEMBL6209873

SCHEMBL6209873

CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2Cl)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 15/20 0.79
PTK2B Q14289 10/20 0.79
ULK1 O75385 2/20 0.79
BCL6 P41182 3/20 0.77
CDK1 P06493 2/20 0.68
CDK7 P50613 2/20 0.68
CCNB1 P14635 1/20 0.68
NTRK1 P04629 3/20 0.53
AURKA O14965 2/20 0.52
BRD4 O60885 1/20 0.52
PLK4 O00444 1/20 0.51
PDPK1 O15530 1/20 0.51
DAPK3 O43293 1/20 0.51
JAK2 O60674 1/20 0.51
ROCK2 O75116 1/20 0.51
STK16 O75716 1/20 0.51
PRKD3 O94806 1/20 0.51
MAP4K4 O95819 1/20 0.51
PAK4 O96013 1/20 0.51
CHEK2 O96017 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6213126 0.93 PTK2 (0.70) PTK2PTK2BULK1BCL6CDK1
SCHEMBL6210615 0.90 PTK2 (0.81) PTK2PTK2BULK1BCL6CDK1
SCHEMBL6210206 0.88 PTK2 (0.70) PTK2PTK2BULK1BCL6CDK1
SCHEMBL3146424 0.88 PTK2 (1.00) PTK2PTK2BULK1BCL6CDK1
SCHEMBL17544462 0.87 PTK2 (0.91) PTK2PTK2BULK1BCL6CDK1
SCHEMBL6211897 0.87 PTK2 (0.78) PTK2PTK2BULK1BCL6CDK1
SCHEMBL17547472 0.84 PTK2 (0.80) PTK2PTK2BULK1BCL6CDK1
SCHEMBL17547558 0.83 PTK2 (0.81) PTK2PTK2BULK1BCL6CDK1
SCHEMBL6210885 0.82 PTK2 (0.67) PTK2PTK2BULK1BCL6CDK1
SCHEMBL6212081 0.82 PTK2 (0.88) PTK2PTK2BULK1BCL6CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US claimed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO claimed
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US disclosed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 PTK2 3004/4885PTK2B 1941/4885ULK1 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.